Human urine proteomics: Building a list of human urine cancer biomarkers

Expert Review of Proteomics

Volumn 8, Issue 3, 2011, Pages 347-360

  Casado Vela, Juan ^a   Del Pulgar, Teresa Gómez ^a   Cebrián, Arancha ^a   Álvarez Ayerza, Nestor ^a   Lacal, Juan Carlos ^a  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

Author keywords

biofluid; blood; bottom up; cancer biomarker; LCMS MS; plasma; protein depletion; urine

Indexed keywords

BIOLOGICAL MARKER; PROTEOME;

AMINO ACID SEQUENCE; CONTAMINATION; DATA BASE; HUMAN; INTERNET; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METHODOLOGY; NEOPLASM; NONHUMAN; PLASMA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN URINE LEVEL; PROTEOMICS; PUBLICATION; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; UNINDEXED SEQUENCE; URINALYSIS;

HUMANS; NEOPLASMS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 79959439343     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/epr.11.26     Document Type: Review

References (114)

1. Haraldsson B, Nystrom J, Deen WM. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol. Rev. 88(2), 451-487 (2008). (Pubitemid 351522745)
2. Said J. Biomarker discovery in urogenital cancer. Biomarkers 10(Suppl. 1), S83-S86 (2005).
3. Kentsis A, Monigatti F, Dorff K et al. Urine proteomics for profiling of human disease using high accuracy mass spectrometry. Proteomics Clin. Appl. 3(9), 1052-1061 (2009
4. Adachi J, Kumar C, Zhang Y, Olsen JV, Mann M. The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol. 7(9), R80 (2006
5. Li QR, Fan KX, Li RX et al. A comprehensive and non-prefractionation on the protein level approach for the human urinary proteome: touching phosphorylation in urine. Rapid Commun. Mass Spectrom. 24(6), 823-832 (2010).
6. Gonzales PA, Pisitkun T, Hoffert JD et al. Large-scale proteomics and phosphoproteomics of urinary exosomes. J. Am. Soc. Nephrol. 20(2), 363-379 (2009).
7. Agron IA, Avtonomov DM, Kononikhin AS et al. Accurate mass tag retention time database for urine proteome analysis by chromatography-mass spectrometry. Biochemistry 75(5), 636-641 (2010).
8. Castagna A, Cecconi D, Sennels L et al. Exploring the hidden human urinary proteome via ligand library beads. J. Proteome Res. 4(6), 1917-1930 (2005). (Pubitemid 41814257)
9. Pisitkun T, Shen RF, Knepper MA. Identification and proteomic profiling of exosomes in human urine. Proc. Natl Acad. Sci. USA 101(36), 13368-13373 (2004). (Pubitemid 39209672)
10. Sun W, Li F, Wu S et al. Human urine proteome analysis by three separation approaches. Proteomics 5(18), 4994-5001 (2005). (Pubitemid 43016918)
11. Wang L, Li F, Sun W et al. Concanavalin A-captured glycoproteins in healthy human urine. Mol. Cell Proteomics 5(3), 560-562 (2006).
12. Pieper R, Gatlin CL, McGrath AM et al. Characterization of the human urinary proteome: a method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots. Proteomics 4(4), 1159-1174 (2004). (Pubitemid 38445973)
13. Tan LB, Chen KT, Yuan YC, Liao PC, Guo HR. Identification of urine PLK2 as a marker of bladder tumors by proteomic analysis. World J. Urol. 28(1), 117-122 (2010).
14. Schaub S, Wilkins J, Weiler T et al. Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int. 65(1), 323-332 (2004). (Pubitemid 38037520)
15. Theodorescu D, Wittke S, Ross MM et al. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol. 7(3), 230-240 (2006). (Pubitemid 43286453)
16. Coon JJ, Zurbig P, Dakna M et al. CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin. Appl. 2(7-8), 964 (2008).
17. Cannas A, Kalunga G, Green C et al. Implications of storing urinary DNA from different populations for molecular analyses. PLoS One 4(9), e6985 (2009).
18. Taylor CF, Paton NW, Lilley KS et al. The minimum information about a proteomics experiment (MIAPE). Nat. Biotechnol. 25(8), 887-893 (2007). (Pubitemid 47236919)
19. Zhang W, Chait BT. ProFound: an expert system for protein identification using mass spectrometric peptide mapping information. Anal. Chem. 72(11), 2482-2489 (2000). (Pubitemid 30395651)
20. Bakalarski CE, Haas W, Dephoure NE, Gygi SP. The effects of mass accuracy, data acquisition speed, and search algorithm choice on peptide identification rates in phosphoproteomics. Anal. Bioanal. Chem. 389(5), 1409-1419 (2007). (Pubitemid 350023665)
21. Elias JE, Gygi SP. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat. Methods 4(3), 207-214 (2007). (Pubitemid 46358868)
22. Casado-Vela J, Cebrian A, Gomez Del Pulgar MT et al. Lights and shadows of proteomic technologies for the study of protein species including isoforms, splicing variants and protein post-translational modifications. Proteomics 11(4), 590-603 (2011).
23. Tamm I, Horsfall FL Jr. A mucoprotein derived from human urine which reacts with influenza, mumps, and Newcastle disease viruses. J. Exp. Med. 95(1), 71-97 (1952).
24. Casado-Vela J, Rodriguez-Suarez E, Iloro I et al. Comprehensive proteomic analysis of human endometrial fluid aspirate. J. Proteome Res. 8(10), 4622-4632 (2009).
25. Makarov A, Denisov E, Kholomeev A et al. Performance evaluation of a hybrid linear ion trap/orbitrap mass spectrometer. Anal. Chem. 78(7), 2113-2120 (2006).
26. Domon B, Aebersold R. Mass spectrometry and protein analysis. Science 312(5771), 212-217 (2006).
27. Shen Y, Kim J, Strittmatter EF et al. Characterization of the human blood plasma proteome. Proteomics 5(15), 4034-4045 (2005). (Pubitemid 41502498)
28. Maurer-Spurej E, Pfeiler G, Maurer N et al. Room temperature activates human blood platelets. Lab. Invest. 81(4), 581-592 (2001). (Pubitemid 32298804)
29. Wang Z, Nicholls SJ, Rodriguez ER et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat. Med. 13(10), 1176-1184 (2007). (Pubitemid 47530630)
30. McCarthy J, Hopwood F, Oxley D et al. Carbamylation of proteins in 2-D electrophoresis-myth or reality? J. Proteome Res. 2(3), 239-242 (2003). (Pubitemid 37099093)
31. Stark GR. Reactions of cyanate with functional groups of proteins. IV. Inertness of aliphatic hydroxyl groups. Formation of carbamyl- and acylhydantoins. Biochemistry 4(11), 2363-2367 (1965).
32. Stark GR. Reactions of cyanate with functional groups of proteins. II. formation, decomposition, and properties of N-carbamylimidazole. Biochemistry 4, 588-595 (1965).
33. Stark GR. Reactions of cyanate with functional groups of proteins. 3. Reactions with amino and carboxyl groups. Biochemistry 4(6), 1030-1036 (1965).
34. Mitra AP, Cote RJ. Molecular screening for bladder cancer: progress and potential. Nat. Rev. Urol. 7(1), 11-20 (2010).
35. Gilbert R. Taking a midstream specimen of urine. Nurs. Times 102(18), 22-23 (2006).
36. Picotti P, Lam H, Campbell D et al. A database of mass spectrometric assays for the yeast proteome. Nat. Methods 5(11), 913-914 (2008
37. Stahl-Zeng J, Lange V, Ossola R et al. High sensitivity detection of plasma proteins by multiple reaction monitoring of N-glycosites. Mol. Cell. Proteomics 6(10), 1809-1817 (2007). (Pubitemid 350031682)
38. Casado-Vela J, Ruiz EJ, Nebreda AR, Casal JI. A combination of neutral loss and targeted product ion scanning with two enzymatic digestions facilitates the comprehensive mapping of phosphorylation sites. Proteomics 7(15), 2522-2529 (2007). (Pubitemid 47253812)
39. Picotti P, Bodenmiller B, Mueller LN, Domon B, Aebersold R. Full dynamic range proteome analysis of S. cerevisiae by targeted proteomics. Cell 138(4), 795-806 (2009).
40. Pritzker KP. Cancer biomarkers: easier said than done. Clin. Chem. 48(8), 1147-1150 (2002).
41. Polanski M, Anderson NL. A list of candidate cancer biomarkers for targeted proteomics. Biomark. Insights 1, 1-48 (2007).
42. Nagaraj N, Mann M. Quantitative analysis of the intra- and inter-individual variability of the normal urinary proteome. J. Proteome Res. 10(2), 637-645 (2011).
43. Decramer S, Gonzalez de Peredo A, Breuil B et al. Urine in clinical proteomics. Mol. Cell Proteomics 7(10), 1850-1862 (2008).
44. Goodison S, Rosser CJ, Urquidi V. Urinary proteomic profiling for diagnostic bladder cancer biomarkers. Expert Rev. Proteomics 6(5), 507-514 (2009).
45. Mohammed SI, Rahman M. Proteomics and genomics of urinary bladder cancer. Proteomics Clin. Appl. 2(9), 1194-1207 (2008).
46. Mor G, Visintin I, Lai Y et al. Serum protein markers for early detection of ovarian cancer. Proc. Natl Acad. Sci. USA 102(21), 7677-7682 (2005). (Pubitemid 40741030)
47. Lemos-Gonzalez Y, Rodriguez-Berrocal FJ, Cordero OJ, Gomez C, Paez de la Cadena M. Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma. Br. J. Cancer 96(10), 1569-1578 (2007). (Pubitemid 46762963)
48. Kyrtsonis MC, Vassilakopoulos TP, Siakantaris MP et al. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease. Eur. J. Haematol. 72(4), 252-258 (2004). (Pubitemid 38406556)
49. Rosenzweig CN, Zhang Z, Sun X et al. Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers. J. Urol. 181(3), 1407-1414 (2009).
50. Boyano MD, Garcia-Vazquez MD, Lopez-Michelena T et al. Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma. Br. J. Cancer 83(7), 847-852 (2000).
51. Tsujisaki M, Imai K, Hirata H et al. Detection of circulating intercellular adhesion molecule-1 antigen in malignant diseases. Clin. Exp. Immunol. 85(1), 3-8 (1991).
52. Altomonte M, Fonsatti E, Lamaj E et al. Differential levels of soluble intercellular adhesion molecule-1 (sICAM-1) in early breast cancer and benign breast lesions. Breast Cancer Res. Treat. 58(1), 19-23 (1999). (Pubitemid 30003867)
53. Lei JY, Wang Y, Jaffe ES et al. Microcystic adnexal carcinoma associated with primary immunodeficiency, recurrent diffuse herpes simplex virus infection, and cutaneous T-cell lymphoma. Am. J. Dermatopathol. 22(6), 524-529 (2000). (Pubitemid 32054847)
54. Pavlov N, Badet J. Angiogenin: involvement in angiogenesis and tumour growth. Bull. Cancer 88(8), 725-732 (2001). (Pubitemid 32896841)
55. Tsukishiro S, Suzumori N, Nishikawa H, Arakawa A, Suzumori K. Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis. Gynecol. Oncol. 96(2), 516-519 (2005). (Pubitemid 40127158)
56. Cheng WL, Wang CS, Huang YH et al. Overexpression of a secretory leukocyte protease inhibitor in human gastric cancer. Int. J. Cancer 123(8), 1787-1796 (2008).
57. Reeves JR, Xuan JW, Arfanis K et al. Identification, purification and characterization of a novel human blood protein with binding affinity for prostate secretory protein of 94 amino acids. Biochem. J. 385(Pt 1), 105-114 (2005).
58. Begum FD, Hogdall CK, Kjaer SK et al. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients. Anticancer Res. 24(3b), 1981-1985 (2004). (Pubitemid 38954621)
59. Brunner A, Ensinger C, Christiansen M et al. Expression and prognostic significance of Tetranectin in invasive and non-invasive bladder cancer. Virchows Arch. 450(6), 659-664 (2007). (Pubitemid 46986224)
60. Arellano-Garcia ME, Li R, Liu X et al. Identification of tetranectin as a potential biomarker for metastatic oral cancer. Int. J. Mol. Sci. 11(9), 3106-3121 (2010).
61. Guzinska-Ustymowicz K, Zalewski B, Kasacka I, Piotrowski Z, Skrzydlewska E. Activity of cathepsin B and D in colorectal cancer: relationships with tumour budding. Anticancer Res. 24(5A), 2847-2851 (2004). (Pubitemid 39407157)
62. Radisky ES. Cathepsin D. Regulation in mammary gland remodeling, misregulation in breast cancer. Cancer Biol. Ther. 10(5), 467-470 (2010).
63. Skates SJ, Horick N, Yu Y et al. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J. Clin. Oncol. 22(20), 4059-4066 (2004). (Pubitemid 41185174)
64. Tamimi RM, Brugge JS, Freedman ML et al. Circulating colony stimulating factor-1 and breast cancer risk. Cancer Res. 68(1), 18-21 (2008). (Pubitemid 351380100)
65. Taysi S, Akcay F, Uslu C, Dogru Y, Gulcin I. Trace elements and some extracellular antioxidant protein levels in serum of patients with laryngeal cancer. Biol. Trace Elem. Res. 91(1), 11-18 (2003). (Pubitemid 36205202)
66. Haouas H, Haouas S, Uzan G, Hafsia A. Identification of new markers discriminating between myeloid and lymphoid acute leukemia. Hematology 15(4), 193-203 (2010).
67. Osunkoya AO, Yin-Goen Q, Phan JH et al. Diagnostic biomarkers for renal cell carcinoma: selection using novel bioinformatics systems for microarray data analysis. Hum. Pathol. 40(12), 1671-1678 (2009).
68. Vose JM, Colcher D, Gobar L et al. Phase I/II trial of multiple dose 131Iodine- MAb LL2 (CD22) in patients with recurrent non-Hodgkins lymphoma. Leuk. Lymphoma 38(1-2), 91-101 (2000). (Pubitemid 30224326)
69. Cao Y, Veitonmaki N, Keough K et al. Elevated levels of urine angiostatin and plasminogen/plasmin in cancer patients. Int. J. Mol. Med. 5(5), 547-551 (2000).
70. Strojan P, Budihna M, Smid L et al. Cathepsin B and L and stefin A and B levels as serum tumor markers in squamous cell carcinoma of the head and neck. Neoplasma 48(1), 66-71 (2001). (Pubitemid 32167709)
71. Lee MJ, Yu GR, Park SH et al. Identification of cystatin B as a potential serum marker in hepatocellular carcinoma. Clin. Cancer Res. 14(4), 1080-1089 (2008
72. Zhang Z, Bast RC, Jr., Yu Y et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 64(16), 5882-5890 (2004). (Pubitemid 39095590)
73. Farias-Eisner G, Su F, Robbins T et al. Validation of serum biomarkers for detection of early- and late-stage endometrial cancer. Am. J. Obstet. Gynecol. 202(1), 73 e71-e75 (2010).
74. McKinney KQ, Lee YY, Choi HS et al. Discovery of putative pancreatic cancer biomarkers using subcellular proteomics. J. Proteomics 74(1), 79-88 (2011).
75. Shi Q, Harris LN, Lu X et al. Declining plasma fibrinogen afragment identifies HER2-positive breast cancer patients and reverts to normal levels after surgery. J. Proteome Res. 5(11), 2947-2955 (2006). (Pubitemid 44749213)
76. Tesarova P, Kvasnicka J, Umlaufova A et al. [Acute phase proteins in female patients with breast carcinoma]. Sb Lek. 104(2), 121-132 (2003).
77. Bachtiar I, Santoso JM, Atmanegara B et al. Combination of a-1-acid glycoprotein and a-fetoprotein as an improved diagnostic tool for hepatocellular carcinoma. Clin. Chim. Acta 399(1-2), 97-101 (2009).
78. Bruno R, Olivares R, Berille J et al. a-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel. Clin. Cancer Res. 9(3), 1077-1082 (2003). (Pubitemid 36323714)
79. Fentz AK, Sporl M, Spangenberg J et al. Detection of colorectal adenoma and cancer based on transthyretin and C3a-desArg serum levels. Proteomics Clin. Appl. 1(6), 536-544 (2007).
80. Liu L, Liu J, Wang Y et al. A combined biomarker pattern improves the discrimination of lung cancer. Biomarkers 16(1), 20-30 (2011).
81. Jou YJ, Lin CD, Lai CH et al. Proteomic identification of salivary transferrin as a biomarker for early detection of oral cancer. Anal. Chim. Acta 681(1-2), 41-48 (2010).
82. Iacobelli S, Sismondi P, Giai M et al. Prognostic value of a novel circulating serum 90K antigen in breast cancer. Br. J. Cancer 69(1), 172-176 (1994). (Pubitemid 24021843)
83. Iacovazzi PA, Trisolini A, Barletta D et al. Serum 90K/MAC-2BP glycoprotein in patients with liver cirrhosis and hepatocellular carcinoma: a comparison with a-fetoprotein. Clin. Chem. Lab. Med. 39(10), 961-965 (2001). (Pubitemid 33062248)
84. Yeshowardhana, Singh VS. Significance of serum phosphohexose isomerase, hexokinase and aldolase in carcinoma ovary. Indian J. Physiol. Pharmacol. 29(1), 51-54 (1985).
85. Strojan P, Oblak I, Svetic B, Smid L, Kos J. Cysteine proteinase inhibitor cystatin C in squamous cell carcinoma of the head and neck: relation to prognosis. Br. J. Cancer 90(10), 1961-1968 (2004). (Pubitemid 38746337)
86. Nishikawa H, Ozaki Y, Nakanishi T et al. The role of cathepsin B and cystatin C in the mechanisms of invasion by ovarian cancer. Gynecol. Oncol. 92(3), 881-886 (2004). (Pubitemid 38251392)
87. Chang KP, Wu CC, Chen HC et al. Identification of candidate nasopharyngeal carcinoma serum biomarkers by cancer cell secretome and tissue transcriptome analysis: potential usage of cystatin A for predicting nodal stage and poor prognosis. Proteomics 10(14), 2644-2660 (2010).
88. Zhu YY, Takashi M, Miyake K, Kato K. An immunochemical and immunohistochemical study of aldolase isozymes in renal cell carcinoma. J. Urol. 146(2), 469-472 (1991).
89. Asaka M, Kimura T, Nishikawa S, Miyazuki T, Alpert E. Decreased serum aldolase B levels in patients with malignant tumors. Cancer 62(12), 2554-2557 (1988). (Pubitemid 19006438)
90. Mikami Y, Hata S, Kiyokawa T, Manabe T. Expression of CD10 in malignant mullerian mixed tumors and adenosarcomas: an immunohistochemical study. Mod. Pathol. 15(9), 923-930 (2002).
91. DallEra MA, True LD, Siegel AF et al. Differential expression of CD10 in prostate cancer and its clinical implication. BMC Urol. 7, 3 (2007).
92. Vizan P, Sanchez-Tena S, Alcarraz- Vizan G et al. Characterization of the metabolic changes underlying growth factor angiogenic activation: identification of new potential therapeutic targets. Carcinogenesis 30(6), 946-952 (2009).
93. Appetecchia M, Mecule A, Pasimeni G et al. Incidence of high chromogranin A serum levels in patients with non metastatic prostate adenocarcinoma. J. Exp. Clin. Cancer Res. 29, 166 (2010).
94. Kwak JY, Ma TZ, Yoo MJ et al. The comparative analysis of serum proteomes for the discovery of biomarkers for acute myeloid leukemia. Exp. Hematol. 32(9), 836-842 (2004).
95. Hughes SJ, Glover TW, Zhu XX et al. A novel amplicon at 8p22-23 results in overexpression of cathepsin B in esophageal adenocarcinoma. Proc. Natl Acad. Sci. USA 95(21), 12410-12415 (1998). (Pubitemid 28483779)
96. Poon RT, Chung KK, Cheung ST et al. Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma. Clin. Cancer Res. 10(12 Pt 1), 4150-4157 (2004). (Pubitemid 38812495)
97. Shariat SF, Youssef RF, Gupta A et al. Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. J. Urol. 183(5), 1744-1750 (2010).
98. Zhou ZQ, Cao WH, Xie JJ et al. Expression and prognostic significance of THBS1, Cyr61 and CTGF in esophageal squamous cell carcinoma. BMC Cancer 9, 291 (2009).
99. Oka R, Sasagawa T, Ninomiya I et al. Reduction in the local expression of complement component 6 (C6) and 7 (C7) mRNAs in oesophageal carcinoma. Eur. J. Cancer 37(9), 1158-1165 (2001).
100. Garnero P, Buchs N, Zekri J et al. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br. J. Cancer 82(4), 858-864 (2000). (Pubitemid 30085239)
101. Chen C, Mendez E, Houck J et al. Gene expression profiling identifies genes predictive of oral squamous cell carcinoma. Cancer Epidemiol. Biomarkers Prev. 17(8), 2152-2162 (2008).
102. Tomasini-Johansson BR, Sundberg C, Lindmark G, Gailit JO, Rubin K. Vitronectin in colorectal adenocarcinoma - synthesis by stromal cells in culture. Exp. Cell Res. 214(1), 303-312 (1994). (Pubitemid 24302406)
103. Kadowaki M, Sangai T, Nagashima T et al. Identification of vitronectin as a novel serum marker for early breast cancer detection using a new proteomic approach. J. Cancer Res. Clin. Oncol. DOI: 10.1007/ s00432-010-0974-9 (2011) (Epub ahead of print).
104. Jung K, Lein M, Stephan C et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int. J. Cancer 111(5), 783-791 (2004). (Pubitemid 39062904)
105. Tomonaga T, Matsushita K, Yamaguchi S et al. Identification of altered protein expression and post-translational modifications in primary colorectal cancer by using agarose two-dimensional gel electrophoresis. Clin. Cancer Res. 10(6), 2007-2014 (2004 (Pubitemid 38375560)
106. Kanoh Y, Ohtani N, Mashiko T et al. Levels of a2 macroglobulin can predict bone metastases in prostate cancer. Anticancer Res. 21(1B), 551-556 (2001). (Pubitemid 32267569)
107. Mazouni C, Baggerly K, Hawke D et al. Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2-positive breast cancer using an LC-MALDI-TOF/MS procedure. Proteomics 10(19), 3525-3532 (2010).
108. Meyer PR, Krugliak L, Neely S et al. Acute leukemias with both myeloid and lymphoid surface markers. Cytoplasmic a-1-anti-chymotrypsin and a-1-anti-trypsin as possible indicators of early granulocytic differentiation. Am. J. Clin. Pathol. 86(4), 461-468 (1986). (Pubitemid 16006870)
109. Kloth JN, Gorter A, Fleuren GJ et al. Elevated expression of SerpinA1 and SerpinA3 in HLA-positive cervical carcinoma. J. Pathol. 215(3), 222-230 (2008). (Pubitemid 351956703)
110. Comunale MA, Rodemich-Betesh L, Hafner J et al. Linkage specific fucosylation of a-1-antitrypsin in liver cirrhosis and cancer patients: implications for a biomarker of hepatocellular carcinoma. PLoS One 5(8), e12419 (2010).
111. Griffiths TR, Brotherick I, Bishop RI et al. Cell adhesion molecules in bladder cancer: soluble serum E-cadherin correlates with predictors of recurrence. Br. J. Cancer 74(4), 579-584 (1996 (Pubitemid 26279053)
112. NCBI Gene www.ncbi.nlm.nih.gov/gene
113. SRM Atlas www.srmatlas.org
114. Urinary Exosome Protein Database http://dir.nhlbi.nih.gov/papers/lkem/ exosome/